4-(1-Bromoethoxy)-1,2-dichlorobenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-Bromoethoxy)-1,2-dichlorobenzene
• 英文别名: 4-(1-bromoethoxy)-1,2-dichlorobenzene
• 化学式: C₈H₇BrCl₂O
• 分子量: 269.95
• InChiKey: LEHUUQKPRBXEKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL
  申请人：STATegics, Inc.

  公开号：US20140142122A1

  公开（公告）日：2014-05-22

  Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.

  本公开涉及的是式I的类似促红细胞生成素化合物，其调节肾脏细胞、神经元、红细胞或其他促红细胞生成素反应细胞的存活、功能或分化。本发明还涉及优先调节表达组织保护性促红细胞生成素受体的细胞的化合物和方法。本发明的化合物在预防和治疗贫血、器官损伤、中枢神经系统疾病等疾病方面有用，并可作为干细胞治疗等细胞治疗的辅助手段。
• US9163027B2
  申请人：——

  公开号：US9163027B2

  公开（公告）日：2015-10-20
• US9657024B2
  申请人：——

  公开号：US9657024B2

  公开（公告）日：2017-05-23
• [EN] SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL<br/>[FR] COMPOSÉS TRIAZOLO-PYRIMIDINES SUBSTITUÉS POUR LA MODULATION DE LA PROLIFÉRATION, LA DIFFÉRENTIATION ET LA SURVIE CELLULAIRES
  申请人：STATEGICS INC

  公开号：WO2014081878A2

  公开（公告）日：2014-05-30

  Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.